Fresh2 Group Limited Stock

Equities

FRES

US03635R2067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-05-28 pm EDT 5-day change 1st Jan Change
0.4 USD +2.04% Intraday chart for Fresh2 Group Limited -14.89% -55.06%
Sales 2021 17.99M 2.48M Sales 2022 12.04M 1.66M Capitalization 65.83M 9.09M
Net income 2021 -119M -16.43M Net income 2022 -102M -14.08M EV / Sales 2021 8.1 x
Net Debt 2021 22.46M 3.1M Net Debt 2022 8.8M 1.21M EV / Sales 2022 6.2 x
P/E ratio 2021
-0.89 x
P/E ratio 2022
-0.61 x
Employees 75
Yield 2021 *
-
Yield 2022
-
Free-Float 68.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.04%
1 week-14.89%
Current month-27.27%
1 month-30.88%
3 months+14.25%
6 months-58.97%
Current year-55.06%
More quotes
1 week
0.35
Extreme 0.35
0.49
1 month
0.35
Extreme 0.35
0.60
Current year
0.30
Extreme 0.2999
0.90
1 year
0.30
Extreme 0.2999
4.83
3 years
0.30
Extreme 0.2999
112.00
5 years
0.30
Extreme 0.2999
243.60
10 years
0.30
Extreme 0.2999
243.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 29 22-10-02
Founder 67 09-12-31
Chief Executive Officer 66 09-12-31
Members of the board TitleAgeSince
Director/Board Member 64 22-10-02
Director/Board Member 55 22-10-02
Chief Executive Officer 66 09-12-31
More insiders
Date Price Change Volume
24-05-28 0.4 +2.04% 20,162
24-05-24 0.392 -1.75% 8,729
24-05-23 0.399 -13.26% 25,330
24-05-22 0.46 -0.02% 20,956
24-05-21 0.4601 -2.11% 93,092

Delayed Quote Nasdaq, May 28, 2024 at 04:30 pm EDT

More quotes
Fresh2 Group Ltd, formerly AnPac Bio-Medical Science Co Ltd, is a biotechnology company mainly engaged in early cancer screening and detection. The Company is engaged in marketing and selling multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. The Company's CDA technology also assists physicians in cancer diagnosis, prognosis and recurrence. The Company provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, Internet, and Web3 transformation of start-ups and traditional enterprises.
More about the company